Search alternatives:
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
e mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
5 w » 5 wt (Expand Search)
Showing 81 - 100 results of 25,261 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ((( 5 w decrease ) OR ( e mean decrease ))))', query time: 0.71s Refine Results
  1. 81
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 82
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 83
    FG-2216 decreased plasma markers of cardiac injury in Nx-Ob-ZSF1 rats.

    FG-2216 decreased plasma markers of cardiac injury in Nx-Ob-ZSF1 rats. by Pierre E. Signore (11218497)

    Published 2021
    Save to List
    Saved in:
  4. 84
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 85
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 86
    Increased levels of PPARγ and decreased levels of adiponectin in thymus from rats administered cocaine for 7 days.

    Increased levels of PPARγ and decreased levels of adiponectin in thymus from rats administered cocaine for 7 days. by Kana Unuma (283272)

    Published 2022
    Save to List
    Saved in:
  7. 87
    Small RNR subunit interaction with Ydj1 is decreased in Ssa3 and Ssa4 cells.

    Small RNR subunit interaction with Ydj1 is decreased in Ssa3 and Ssa4 cells. by Laura E. Knighton (5991239)

    Published 2022
    Save to List
    Saved in:
  8. 88
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 89
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 90
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 91
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 92
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 93
    Life expectancy (<i>e</i><sub><i>xj</i></sub>) of <i>A</i>. <i>glycines</i>.

    Life expectancy (<i>e</i><sub><i>xj</i></sub>) of <i>A</i>. <i>glycines</i>. by Aonan Zhang (8933630)

    Published 2021
    Save to List
    Saved in:
  14. 94
    Life expectancy (<i>e</i><sub><i>xj</i></sub>) of <i>A</i>. <i>glycines</i>.

    Life expectancy (<i>e</i><sub><i>xj</i></sub>) of <i>A</i>. <i>glycines</i>. by Aonan Zhang (8933630)

    Published 2021
    Save to List
    Saved in:
  15. 95
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 96
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 97
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 98
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 99
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 100
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: